Lancashire and South Cumbria
Formulary
Formulary
6 Endocrine system
06-05-02 Posterior pituitary hormones
| Desmopressin injection |
|
Formulary
|
 NICE CG111: Bedwetting in under 19s |
|
| Desmopressin tablets and spray |
|
Formulary
|
Tablets 100micrograms, 200micrograms
|
|
Medicines for children: Desmopressin for bedwetting MHRA: Desmopressin nasal spray: removal of nocturnal enuresis indication NICE CG111: Bedwetting in under 19s |
|
Links
Biosimilars policy statement- Diabetes UK: Diabetes when you’re unwell
- LSCMMG: Diabetes - Choice of Safety Pen Needles and Lancets
- LSCMMG: Diabetes - Pen Needles/Lancets
- LSCMMG: Diabetes - Position Statement Safety Needles and Safety Lancets
- LSCMMG: Diabetes Guideline for antihyperglycaemic therapy in adults with type 2 diabetes
- LSCMMG: Diabetes: Recommended meters, strips and devices
LSCMMG: GLP-1 patient contract- LSCMMG: Osteoporosis: Secondary fracture prevention patient treatment pathway
- LSCMMG: Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus
- LSCMMG: Tolvaptan NMR
- LSCMMG: Trans Female Gender Dysphoria Information Sheet
- LSCMMG: Trans Male Gender Dysphoria Information Sheet
- Medicines for children: Desmopressin for bedwetting
- MHRA: Desmopressin nasal spray: removal of nocturnal enuresis indication
- MHRA: Diabetes and driving
- MHRA: Terlipressin: new recommendations to reduce risks of respiratory failure and septic shock in patients with type 1 hepatorenal syndrome
- NHSE guidance to primary care about unregulated providers who supply hormone medications to children and young people for gender incongruence
- NICE CG111: Bedwetting in under 19s
- NICE CG111: Bedwetting in under 19s
- NICE CG141: Acute upper gastrointestinal bleeding in over 16s: management
- NICE NG17: Type 1 diabetes in adults: diagnosis and management
- NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG28: Type 2 diabetes in adults: management
- NICE NG3: Diabetes in pregnancy: management from preconception to the postnatal period
- NICE TA358 Tolvaptan for treating autosomal dominant polycystic kidney disease